This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | MicrobiomeTrials
← Back to trials NCT06306014
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-05-07Est. Completion: 2027-01-07
Enrollment target: 56 participantsLocations CH Annecy Genevois Service de Maladies infectieuses, Annecy, France Service d'hépato-gastroentérologie - CHU Estaing, Clermont-Ferrand, France CHU Grenoble Service Maladies infectieuses et tropicales, Grenoble, France Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse, Lyon, France APHM La Timone Service de Maladies infectieuses, Marseille, France Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP), Paris, France Service d'infectiologie - Hôpital Nord / CHU Saint Etienne, Saint-Etienne, France Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse, Toulouse, France Service de Maladies Infectieuses - CH de Valence, Valence, France Other microbiome trials you might be interested in Acute Leukemia in Remission Myelodysplastic Syndromes Myeloproliferative Syndrome Hodgkin Lymphoma Lymphoma, Non-Hodgkin Myeloma Chronic Lymphocytic Leukemia
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…
Amiens, France Est. completion May 2030
Ulcerative Colitis (UC) Inflammatory Bowel Disease (IBD) Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye) Est. completion May 30, 2027
Dysbiosis Clostridium Difficile Pet-Human Bonding Antibiotic-Associated Colitis
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a diseas…
Philadelphia, United States Est. completion Sep 1, 2026